WO2026007196 - ANTIBODY SPECIFICALLY BINDING TO FGFR2B AND DRUG CONJUGATE THEREOF
National phase entry is expected:
Publication Number
WO/2026/007196
Publication Date
08.01.2026
International Application No.
PCT/CN2024/110924
International Filing Date
09.08.2024
Title **
[English]
ANTIBODY SPECIFICALLY BINDING TO FGFR2B AND DRUG CONJUGATE THEREOF
[French]
ANTICORPS SE LIANT DE MANIÈRE SPÉCIFIQUE À FGFR2B ET CONJUGUÉ DE MÉDICAMENT ASSOCIÉ
[Chinese]
特异性结合FGFR2b的抗体及其与药物的缀合物
Applicants **
ABIOTECH PHARMACEUTICAL CO., LTD
Inventors
KONG, Yirong
YU, Ziyi
GAO, Yonghong
ZHANG, Qingjun
HUANG, Zhen
WANG, Xiaojing
LIU, Ye
HOU, Xiaoshuang
LI, Xianzhong
BAI, Xianhong
Priority Data
202410882037.5
02.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2155 | |
| EPO | Filing, Examination, Granting | 14172 | |
| Japan | Filing, Examination, Granting | 2234 | |
| South Korea | Filing, Examination, Granting | 2238 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,539
Contact Us
Abstract[English]
The present document provides a monoclonal antibody specifically binding to fibroblast growth factor receptor 2b (FGFR2b) and an antigen-binding fragment thereof, and further comprises an antibody drug conjugate (ADC), and a use of the anti-FGFR2b antibody or ADC in cancer treatment. The antibody drug conjugate comprises an anti-FGFR2 antibody or an antigen-binding fragment thereof linked to a cytotoxic agent or another component.[French]
Le présent document concerne un anticorps monoclonal se liant spécifiquement au récepteur 2b du facteur de croissance des fibroblastes (FGFR2b) et un fragment de liaison à l'antigène de celui-ci, et comprend en outre un conjugué anticorps-médicament (ADC), et une utilisation de l'anticorps anti-FGFR2b ou de l'ADC dans le traitement du cancer. Le conjugué anticorps-médicament comprend un anticorps anti-FGFR2 ou un fragment de liaison à l'antigène de celui-ci lié à un agent cytotoxique ou à un autre composant.[Chinese]
提供了与成纤维细胞生长因子受体2b（FGFR2b）特异性结合的单克隆抗体和其抗原结合片段，还包含抗体药物缀合物（ADC），以及使用所述抗FGFR2b抗体或ADC在癌症治疗中的应用，其中所述抗体药物缀合物包括与细胞毒性剂或其它部分连接的抗FGFR2抗体或其抗原结合片段。